Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA71508)
Received: 27 February 2018
Accepted: 10 October 2018
First Online: 29 October 2018
: A.W. declares competing interests since he is named as inventor on a Georgetown University patent related to treatments for lowering glucose levels using FGFBP3, described in this manuscript. All other authors have declared that no conflict of interest exists.